DISCUSSION In this medical claims study including 62% of the US population, we observe fewer than 70,000 patients received monoclonal antibody treatments for COVID-19 between first FDA emergency use authorization and April 11, 2021. The Food and Drug Administration (FDA) has issued emergency use authorizations for three monoclonal antibodies for the outpatient treatment of symptomatic coronavirus disease 2019 (COVID-19)[1] in patients at high risk for progressing to severe disease, and the federal government has purchased and allocated nearly 1 million antibody treatments.[2] Monoclonal antibodies remain the only approved outpatient therapies available for COVID-19 and media reports have speculated they may be underutilized;[3] however, data on utilization has not been published. The public interest would be well-served by improved transparency on the allocation and administration of monoclonal antibody treatments, including data necessary to assess equitable access to treatments. [Extracted from the article]